Transcriptomic analysis reveals noncoding RNAs as biomarkers for COVID-19 severity, implying potential clinical applications.
Our findings are consistent with recent patents (e.g., "US20220298584A1", "EP3892280A3", "WO2023147669A1") that propose the use of noncoding RNAs and cytokines as biomarkers for COVID-19 diagnosis and severity assessment. This integrative transcriptomic analysis highlights the regulatory role of noncoding RNAs in COVID-19 progression, exemplified by the central hub lncRNAs NEAT1 and MALAT1, which interact with inflammation- associated miRNAs and mRNA targets to modulate cytokine signaling. These findings offer specific transcriptomic biomarkers with potential for clinical application and therapeutic targeting.
No takes yet. Share an insight, caveat, or question.
Sabetian et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: